Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
Endocrine Oncology · 2022
DOI: 10.1530/eo-21-0021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Oncology, 2022. Verfasst von Nadia Gagnon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Department of Medicine, Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, …. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study examined the magnitude of changes and the time required to observe maximal changes in LDL-c, HDL-c, triglycerides (Tg) and non-HDL-c after the introduction of mitotane.
Methods
Retrospective study of 45 patients with adrenocortical carcinoma who were treated at the Centre hospitalier de l’Université de Montréal. Clinical and biochemical data were collected, including lipid profiles before and during the first year of treatment with mitotane.
Results
Among the 45 studied patients, 26 (58%) had a complete lipid profile before the introduction of mitotane and at least 1 lipid profile during the first year of treatment, and 19 patients (42%) had a lipid profile following initiation of the treatment. Among the 26 patients who had lipid profiles before and after the introduction of mitotane, the increase of LDL-c was 2.19 mmol/L (76%) ( P < 0.0001), HDL-c was 0.54 mmol/L (35%) ( P = 0.0002), Tg was 1.80 mmol/L (129%) ( P < 0.0001) and non-HDL-c was 2.73 mmol/L (79%) ( P < 0.0001). Between the first and the sixth month of mitotane treatment, peak values ( n = 45) of LDL-c and non-HDL-c were reached in 42 patients (93%) and 37 patients (82%), respectively, whereas peak values of HDL-c were reached after 6 months of mitotane treatment in 29 patients (66%). The peak value of Tg was almost equal throughout the first year. The mean peak values of HDL-c, Tg and non-HDL-c showed significant associations with their respective mitotane concentrations (β = 0.352, P = 0.03; β = 0.406, P = 0.02 and β = 0.339, P = 0.05).
Conclusion
The introduction of mitotane produces a clinically significant elevation of lipid parameters (LDL-c, HDL-c, Tg and non-HDL-c) during the first year of treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology, Department of Medicine, Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada.
- Lipids, Nutrition and Cardiovascular Prevention Clinic of the Montreal Clinical Research Institute, Montreal, Québec, Canada.
- Department of Biochemistry, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.
- Department of Medicine, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.
ORCID-Profile: Nadia Gagnon
Zitieren
APA
Gagnon, N., Bernard, S., Paquette, M., Alguire, C., Lacroix, A., Hétu, P. O., Olney, H. J., & Bourdeau, I. (2022). Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma. Endocrine Oncology. https://doi.org/10.1530/eo-21-0021
Vancouver
Gagnon N, Bernard S, Paquette M, Alguire C, Lacroix A, Hétu PO, et al. Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma. Endocrine Oncology. 2022. doi:10.1530/eo-21-0021
BibTeX
@article{Gagnon2022,
author = {Gagnon, Nadia and Bernard, Sophie and Paquette, Martine and Alguire, Catherine and Lacroix, André and Hétu, Pierre-Olivier and Olney, Harold J and Bourdeau, Isabelle},
title = {Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma},
journal = {Endocrine Oncology},
year = {2022},
doi = {10.1530/eo-21-0021}
}
EUVIMED